Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study

B. M. Bonora,G. Russo,F. Leonetti,M. Strazzabosco,L. Nollino,G. Aimaretti,A. Giaccari,F. Broglio,A. Consoli,A. Avogaro,G. P. Fadini,

DOI: https://doi.org/10.1007/s40618-024-02309-2

2024-02-18

Journal of Endocrinological Investigation

Abstract:Abstract Aim Oral semaglutide, an innovative orally administered GLP-1 receptor agonist for type 2 diabetes (T2D) management was herein evaluated for its effectiveness in a multi-center retrospective real-world study. Methods We included new-users of oral semaglutide from 18 specialist care centres and collected retrospective data on baseline clinical characteristics. Updated values of HbA1c and body weight were analyzed using the mixed model for repeated measures. Results The study included 166 individuals with T2D, predominantly men (64.5%), with a mean age of 64.4 years and a mean diabetes duration of 10.1 years. In the majority of patients (68.3%) oral semaglutide was used as a second-line drug, mostly with metformin. At baseline, mean BMI was 28.9 kg/m 2 and HbA1c was 7.5%. During the 18-month observation period, oral semaglutide demonstrated significant reductions in HbA1c, with a maximum change of − 0.9%, and 42.1% of patients achieved HbA1c values below 7.0%. Additionally, there was a substantial reduction in body weight, with an estimated change of − 3.4 kg at 18 months, and 30.3% of patients experienced a 5% or greater reduction in baseline body weight. Only 24.2% of patients reached the 14 mg dose. Subgroup analysis revealed that baseline HbA1c > 7%, persistence on drug, not being on a prior therapy with DPP-4 inhibitors, and loosing 5% or more the initial body weight were associated with greater HbA1c reductions. Conclusion This study supports oral semaglutide as an effective option for T2D treatment, offering improved glucose control and weight management in a real-world setting.

endocrinology & metabolism

What problem does this paper attempt to address?

The paper aims to address the efficacy of oral semaglutide in the management of type 2 diabetes (T2D). Specifically, the study evaluates the impact of oral semaglutide on glycemic control and weight through a multicenter retrospective real-world study.

### Research Background
- **Drug Introduction**: Oral semaglutide is an innovative oral GLP-1 receptor agonist used for the treatment of type 2 diabetes.
- **Existing Evidence**: Previous studies have shown that oral semaglutide is superior to existing oral T2D treatments in terms of glycemic control and weight management, and it has the potential to improve cardiovascular risk markers.
- **Research Objective**: To evaluate the efficacy and safety of oral semaglutide in a real-world setting.

### Main Findings
- **Study Subjects**: Included 166 patients with type 2 diabetes, with an average age of 64.4 years and an average diabetes duration of 10.1 years.
- **Primary Results**:
- During the 18-month observation period, oral semaglutide significantly reduced HbA1c levels, with a maximum change of -0.9%, and 42.1% of patients had HbA1c values reduced to below 7.0%.
- Weight also significantly decreased, with an estimated change of -3.4kg, and 30.3% of patients experienced a weight reduction of 5% or more.
- **Dose Analysis**: Only 24.2% of patients reached the maximum dose of 14mg.
- **Subgroup Analysis**: Greater reductions in HbA1c were associated with patients who had baseline HbA1c > 7%, continued medication use, no prior DPP-4 inhibitor treatment, and weight loss of more than 5%.

### Conclusion
The study supports oral semaglutide as an effective treatment option for type 2 diabetes, providing better glycemic control and weight management in a real-world setting.